Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Tyrosine
Accession Number
DB00135  (NUTR00059)
Type
Small Molecule
Groups
Approved, Investigational, Nutraceutical
Description

Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

Structure
Thumb
Synonyms
  • (−)-α-amino-p-hydroxyhydrocinnamic acid
  • (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
  • (S)-(-)-Tyrosine
  • (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
  • (S)-3-(p-Hydroxyphenyl)alanine
  • (S)-alpha-amino-4-Hydroxybenzenepropanoic acid
  • (S)-Tyrosine
  • (S)-α-amino-4-hydroxybenzenepropanoic acid
  • 4-hydroxy-L-phenylalanine
  • L-Tyrosin
  • L-tyrosine
  • Tirosina
  • Tyr
  • Tyrosine
  • Tyrosinum
  • Y
External IDs
FEMA NO. 3736
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
2.5% Travasol Amino Acid Injection With Electrolytes In 10% DextroseTyrosine (10 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Leucine (182.5 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Valine (145 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312015-08-05Canada
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose ClinimixTyrosine (10 mg) + Alanine (520 mg) + Arginine (260 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (520 mg) + Histidine (110 mg) + Isoleucine (120 mg) + L-Lysine hydrochloride (145 mg) + L-Leucine hydrochloride (155 mg) + Magnesium chloride (25.5 mg) + Methionine (145 mg) + Phenylalanine hydrochloride (155 mg) + Proline (105 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Valine (115 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312015-08-05Canada
2.5% Travasol Amino Acid Injection Without Electrolytes In 10% Dextrose QuickmixTyrosine (10 mg) + Alanine (520 mg) + Arginine (260 mg) + Dextrose, unspecified form (10 g) + Glycine (520 mg) + Histidine (110 mg) + Isoleucine (120 mg) + L-Lysine hydrochloride (195 mg) + L-Leucine hydrochloride (155 mg) + Methionine (195 mg) + Phenylalanine hydrochloride (155 mg) + Proline (105 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Valine (115 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312007-08-02Canada
2.5%travasol Amino Acid InJ.W.eleC.W.25%dexTyrosine (10 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Leucine (182.5 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Serine (125 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Valine (145 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travas. Amino Acid InJ.W.elecw.25%dexTyrosine (11 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Leucine (201 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Valine (159.5 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose QuickmixTyrosine (11 mg) + Alanine (570 mg) + Arginine (285 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Lysine hydrochloride (159 mg) + L-Leucine hydrochloride (170 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Phenylalanine hydrochloride (170 mg) + Proline (115 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Threonine (115 mg) + Tryptophan (49.5 mg) + Valine (126 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-02-022007-08-02Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 5% Dextrose QuickmixTyrosine (11 mg) + Alanine (570 mg) + Arginine (285 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (215.5 mg) + Glycine (570 mg) + Histidine (120.5 mg) + Isoleucine (131.5 mg) + L-Lysine hydrochloride (159 mg) + L-Leucine hydrochloride (170 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Phenylalanine hydrochloride (170 mg) + Proline (115 mg) + Sodium acetate (256 mg) + Sodium chloride (112 mg) + Threonine (115 mg) + Tryptophan (49.5 mg) + Valine (126 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312007-08-02Canada
2.75%travasol Amino Acid InJ.W.eleC.W.5%dex.Tyrosine (11 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Leucine (201 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Serine (137.5 mg) + Sodium acetate (215 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Valine (159.5 mg)LiquidIntravenousClintec Nutrition Company1996-12-311999-08-10Canada
20% ProsolTyrosine (0.05 g) + Alanine (2.76 g) + Arginine (1.96 g) + Aspartic acid (0.6 g) + D-Methionine (0.76 g) + Glutamic acid (1.02 g) + Glycine (2.06 g) + Histidine (1.18 g) + Isoleucine (1.08 g) + L-Lysine (1.35 g) + Leucine (1.08 g) + Methionine (0.76 g) + Phenylalanine (1 g) + Proline (1.34 g) + Serine (1.02 g) + Threonine (0.98 g) + Tryptophan (0.32 g) + Valine (1.44 g)LiquidIntravenousBaxter Laboratories1996-10-09Not applicableCanada
4.25% Amino Acid Injection Without Electrolytes In 20% Dextrose QuickmixTyrosine (17 mg) + Alanine (880 mg) + Arginine (440 mg) + Dextrose, unspecified form (20 g) + Glycine (880 mg) + Histidine (186 mg) + Isoleucine (203 mg) + L-Lysine hydrochloride (246 mg) + L-Leucine hydrochloride (263 mg) + Methionine (246 mg) + Phenylalanine hydrochloride (263 mg) + Proline (178 mg) + Threonine (178 mg) + Tryptophan (76 mg) + Valine (195 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312007-08-02Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AppbutamoneTyrosine (100 mg/1) + Bupropion hydrochloride (75 mg/1)KitOralPhysician Therapeutics Llc2011-07-07Not applicableUs
Appbutamone-DTyrosine (100 mg/1) + Bupropion hydrochloride (75 mg/1)KitOralPhysician Therapeutics Llc2011-07-07Not applicableUs
AppforminTyrosine (100 mg/1) + Metformin hydrochloride (500 mg/1)KitOralPhysician Therapeutics Llc2011-02-07Not applicableUs
Appformin-DTyrosine (100 mg/1) + Metformin hydrochloride (500 mg/1)KitOralPhysician Therapeutics Llc2011-07-07Not applicableUs
ClinimixTyrosine (0.34 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Dipotassium phosphate (5.22 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + L-Lysine (4.93 g/2L) + Leucine (6.20 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Threonine (3.57 g/2L) + Tryptophan (1.53 g/2L) + Valine (4.93 g/2L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30Us
ClinimixTyrosine (0.11 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Valine (1.60 g/1L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30Us
ClinimixTyrosine (0.11 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Valine (1.60 g/1L)SolutionIntravenousBaxter Healthcare Corporation2017-10-252019-11-30Us
PrimeneTyrosine (0.11 g/250mL) + Alanine (2 g/250mL) + Arginine (2.1 g/250mL) + Aspartic acid (1.5 g/250mL) + Glutamic acid (2.5 g/250mL) + Glycine (1 g/250mL) + Histidine (0.95 g/250mL) + Isoleucine (1.675 g/250mL) + L-Cysteine (0.47 g/250mL) + L-Lysine (2.75 g/250mL) + Leucine (2.5 g/250mL) + Methionine (0.6 g/250mL) + Ornithine hydrochloride (0.8 g/250mL) + Phenylalanine (1.05 g/250mL) + Proline (0.75 g/250mL) + Serine (1 g/250mL) + Taurine (0.15 g/250mL) + Threonine (0.9 g/250mL) + Tryptophan (0.5 g/250mL) + Valine (1.9 g/250mL)Injection, solutionIntravenousBaxter Healthcare Corporation2017-11-22Not applicableUs
SynthaminTyrosine (400 mg/1000mL) + Alanine (20.70 g/1000mL) + Arginine (11.50 g/1000mL) + Glycine (10.30 g/1000mL) + Histidine (4.80 g/1000mL) + Isoleucine (6 g/1000mL) + L-Lysine (5.80 g/1000mL) + Leucine (7.30 g/1000mL) + Methionine (4 g/1000mL) + Phenylalanine (5.60 g/1000mL) + Proline (6.80 g/1000mL) + Serine (5 g/1000mL) + Threonine (4.20 g/1000mL) + Tryptophan (1.80 g/1000mL) + Valine (5.80 g/1000mL)Injection, solutionIntravenousBaxter Healthcare Corporation2017-11-03Not applicableUs
Categories
UNII
42HK56048U
CAS number
60-18-4
Weight
Average: 181.1885
Monoisotopic: 181.073893223
Chemical Formula
C9H11NO3
InChI Key
OUYCCCASQSFEME-QMMMGPOBSA-N
InChI
InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
IUPAC Name
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
SMILES
N[C@@H](CC1=CC=C(O)C=C1)C(O)=O

Pharmacology

Indication

Tyrosine is claimed to act as an effective antidepressant, however results are mixed. Tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies.

Pharmacodynamics

Tyrosine is a nonessential amino acid synthesized in the body from phenylalanine. Tyrosine is critical for the production of the body's proteins, enzymes and muscle tissue. Tyrosine is a precursor to the neurotransmitters norepinephrine and dopamine. It can act as a mood elevator and an anti-depressant. It may improve memory and increase mental alertness. Tyrosine aids in the production of melanin and plays a critical role in the production of thyroxin (thyroid hormones). Tyrosine deficiencies are manifested by hypothyroidism, low blood pressure and low body temperature. Supplemental tyrosine has been used to reduce stress and combat narcolepsy and chronic fatigue.

Mechanism of action

Tyrosine is produced in cells by hydroxylating the essential amino acid phenylalanine. This relationship is much like that between cysteine and methionine. Half of the phenylalanine required goes into the production of tyrosine; if the diet is rich in tyrosine itself, the requirements for phenylalanine are reduced by about 50%. The mechanism of L-tyrosine's antidepressant activity can be accounted for by the precursor role of L-tyrosine in the synthesis of the neurotransmitters norepinephrine and dopamine. Elevated brain norepinephrine and dopamine levels are thought to be associated with antidepressant effects.

TargetActionsOrganism
UTyrosine 3-monooxygenase
binder
Humans
UTyrosine--tRNA ligase, mitochondrialNot AvailableHumans
UTyrosine--tRNA ligase, cytoplasmicNot AvailableHumans
UTyrosine aminotransferaseNot AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

L-tyrosine is absorbed from the small intestine by a sodium-dependent active transport process.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

In the liver, L-tyrosine is involved in a number of biochemical reactions, including protein synthesis and oxidative catabolic reactions. L-tyrosine that is not metabolized in the liver is distributed via the systemic circulation to the various tissues of the body.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

L-Tyrosine has very low toxicity. There have been very few reports of toxicity. LD50 (oral, rat) > 5110 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Aromatic L-Aminoacid Decarboxylase DeficiencyDisease
PhenylketonuriaDisease
Tyrosine MetabolismMetabolic
Catecholamine BiosynthesisMetabolic
Tyrosinemia Type IDisease
Tyrosinemia Type 3 (TYRO3)Disease
Disulfiram Action PathwayDrug action
Phenylalanine and Tyrosine MetabolismMetabolic
AlkaptonuriaDisease
HawkinsinuriaDisease
Tyrosinemia Type 2 (or Richner-Hanhart Syndrome)Disease
Tyrosinemia, Transient, of the NewbornDisease
Tyrosine Hydroxylase DeficiencyDisease
Dopamine beta-Hydroxylase DeficiencyDisease
Monoamine Oxidase-A Deficiency (MAO-A)Disease
Thyroid Hormone SynthesisMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

Synthesis Reference

Hai-quan Mao, Kam W. Leong, "Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same." U.S. Patent US5912225, issued May, 1960.

US5912225
General References
  1. Hoffhines AJ, Damoc E, Bridges KG, Leary JA, Moore KL: Detection and purification of tyrosine-sulfated proteins using a novel anti-sulfotyrosine monoclonal antibody. J Biol Chem. 2006 Dec 8;281(49):37877-87. Epub 2006 Oct 17. [PubMed:17046811]
  2. Molnar GA, Wagner Z, Marko L, Ko Szegi T, Mohas M, Kocsis B, Matus Z, Wagner L, Tamasko M, Mazak I, Laczy B, Nagy J, Wittmann I: Urinary ortho-tyrosine excretion in diabetes mellitus and renal failure: evidence for hydroxyl radical production. Kidney Int. 2005 Nov;68(5):2281-7. [PubMed:16221230]
  3. Molnar GA, Nemes V, Biro Z, Ludany A, Wagner Z, Wittmann I: Accumulation of the hydroxyl free radical markers meta-, ortho-tyrosine and DOPA in cataractous lenses is accompanied by a lower protein and phenylalanine content of the water-soluble phase. Free Radic Res. 2005 Dec;39(12):1359-66. [PubMed:16298866]
External Links
Human Metabolome Database
HMDB0000158
KEGG Drug
D00022
KEGG Compound
C00082
PubChem Compound
6057
PubChem Substance
46507885
ChemSpider
5833
BindingDB
18129
ChEBI
58315
ChEMBL
CHEMBL925
Therapeutic Targets Database
DAP000808
PharmGKB
PA451822
HET
TYR
PDRhealth
PDRhealth Drug Page
Wikipedia
Tyrosine
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingSupportive CareProtein Feeding in Post-traumatic Injury Patients1
1Active Not RecruitingTreatmentAdvanced Cancers / Advanced Malignant Neoplasm / BRAF Gene Mutation / Metastatic Malignant Neoplasm / Recurrent Malignant Neoplasm / Refractory Malignant Neoplasm1
1Active Not RecruitingTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1Active Not RecruitingTreatmentLung Cancers / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage II Non-Small Cell Lung Cancer AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
1CompletedPreventionBMI >30 kg/m21
1CompletedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Anaplastic Oligoastrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Tumor / Tumors Metastatic to Brain1
1CompletedTreatmentChildhood Solid Neoplasm / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
1RecruitingNot AvailableLung Cancers1
1RecruitingTreatmentAcute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Fibroblast Growth Factor Basic Form Measurement / FLT3 Internal Tandem Duplication / Recurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
1RecruitingTreatmentAdenocarcinoma Of Esophagus / Colorectal Cancers / Hepatocellular,Carcinoma / Malignant Neoplasm of Stomach1
1RecruitingTreatmentAdvanced Malignant Solid Neoplasm / KRAS Gene Mutation / Ovarian Carcinoma / Refractory Malignant Solid Neoplasm / Refractory Ovarian Carcinoma1
1RecruitingTreatmentDiffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Lymphoma, Large B-Cell, Diffuse (DLBCL) / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
1RecruitingTreatmentEGFR Negative Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Stage IV Non-Small Cell Lung Cancer1
1SuspendedTreatmentStage I Prostate Adenocarcinoma / Stage II Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma1
1TerminatedTreatmentNon-small Cell Lung Cancer (NSCLC), Recurrent / Non-small Cell Lung Cancer (NSCLC), Stage IV / Non-Small Cell Lung Cancer Recurrent / Stage IV Non-Small Cell Lung Cancer1
1WithdrawnTreatmentDuct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentALK Fusion Protein Expression / ALK Gene Amplification / ALK Gene Mutation / ALK positive / Brain and Central Nervous System Tumors / C-MET Gene Amplification / Malignant Lymphomas / MET Gene Mutation / Neuroblastomas / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Refractory Anaplastic Large Cell Lymphoma / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentRecurrent IDHwt Gliomas With FGFR1-TACC1 Fusion / Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion1
1, 2Not Yet RecruitingTreatmentChronic Myeloid Leukemia, Chronic Phase1
1, 2Not Yet RecruitingTreatmentEGFR Mutation Positive Non Small Cell Lung Cancer1
1, 2RecruitingPreventionGraft Versus Host Disease (GVHD) / Lung Cancers1
1, 2RecruitingTreatmentKidney Transplant Rejection1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Extensive Stage Small Cell Lung Cancer / Limited Stage Small Cell Lung Cancer / Non-Small Cell Lung Cancer Recurrent / Refractory Small cell lung cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentCarcinoid Tumors / Metastatic Carcinoid Tumors / Neuroendocrine Neoplasms1
2Active Not RecruitingTreatmentColon Adenocarcinoma / Rectal Adenocarcinoma / Recurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2Active Not RecruitingTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentEGFR Activating Mutation / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)1
2Active Not RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent / Squamous Cell Carcinoma of Lung / Stage III Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Primary Peritoneal Cancer / Recurrent, Epithelial Ovarian Cancer1
2Active Not RecruitingTreatmentRecurrent Pleural Malignant Mesothelioma / Stage IV Pleural Mesothelioma1
2CompletedSupportive CareLung Non-Squamous Non-Small Cell Carcinoma / Radiation-Induced Pneumonitis / Stage II Lung Non-Small Cell Cancer AJCC v7 / Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage III Lung Non-Small Cell Cancer AJCC v7 / Stage IIIA Lung Non-Small Cell Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Lung Non-Small Cell Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IV Lung Non-Small Cell Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentCarcinoid Tumors1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mucinous Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Transitional Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm / Recurrent Uterine Corpus Carcinoma1
2CompletedTreatmentMetastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2Enrolling by InvitationTreatmentSolid Cancers1
2Not Yet RecruitingPreventionSepsis1
2Not Yet RecruitingTreatmentCarcinosarcoma of Ovary / Carcinosarcoma of Uterus / Carcinosarcoma of Vagina1
2Not Yet RecruitingTreatmentChronic Lymphocytic Leukemia (CLL) - Refractory / Chronic, recurrent Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Small Lymphocytic Lymphoma1
2Not Yet RecruitingTreatmentLeukemia, Myelogenous, Chronic, BCR-ABL Positive1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2RecruitingDiagnosticIntracranial Neoplasm / Low Grade Glioma (LGG) / Recurrent Glioblastoma / Recurrent WHO Grade III Glioma / Recurrent World Health Organization (WHO) Grade II Glioma1
2RecruitingTreatmentALK Gene Rearrangement / ALK positive / Lung Non-Squamous Non-Small Cell Carcinoma / Non-Squamous Non-Small Cell Lung Carcinoma / Stage IV Lung Cancer AJCC v8 / Stage IVA Lung Cancer AJCC v8 / Stage IVB Lung Cancer AJCC v81
2RecruitingTreatmentAcute Respiratory Failure1
2RecruitingTreatmentAdvanced Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Bladder Carcinoma / Carcinoma, Breast / Carcinoma, Colorectal / Carcinoma, Pancreatic / Cervical Carcinoma / Colon Carcinoma / Endometrial Carcinoma / Esophageal Carcinoma / Gastric Carcinoma / Gliomas / Head and Neck Carcinoma / Liver and Intrahepatic Bile Duct Carcinoma / Lung, Carcinoma / Malignant Lymphomas / Malignant Uterine Neoplasm / Melanoma / Ovarian Carcinoma / Plasma Cell Myeloma / Prostate Cancer / Rectal Carcinoma / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Cervical Carcinoma / Recurrent Colon Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Gliomas / Recurrent Head and Neck Carcinoma / Recurrent Liver Carcinoma / Recurrent Lung Carcinoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Plasma Cell Myeloma / Recurrent Prostate Carcinoma / Recurrent Rectal Carcinoma / Recurrent Skin Carcinoma / Recurrent Solid Neoplasm / Recurrent Thyroid Gland Carcinoma / Recurrent Uterine Corpus Carcinoma / Refractory Lymphomas / Refractory Malignant Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Plasma Cell Myeloma / Renal Carcinoma / Skin Carcinoma / Solid Neoplasms / Thyroid Gland Carcinoma / Uterine Corpus Cancer1
2RecruitingTreatmentBlastoid Variant Mantle Cell Lymphoma / CCND1 Protein Overexpression / CD20 Positive / CD5 Positive / FCER2 Negative / Pleomorphic Variant Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma / T(11;14)(q13;q32)1
2RecruitingTreatmentCCND1 Negative / Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma / T(11;14) Negative1
2RecruitingTreatmentCCND1 Positive / Liver Lymphoma / Mantle Cell Lymphoma (MCL) / T(11;14) Positive1
2RecruitingTreatmentChronic Myeloid Leukemia, Chronic Phase / Chronic Phase Chronic Myeloid Leukemia1
2RecruitingTreatmentChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2RecruitingTreatmentNeoplasms, Malignant1
2RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V7 / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Unresectable Renal Cell Carcinoma1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / Ann Arbor Stage II Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Childhood Anaplastic Large Cell Lymphoma / Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2TerminatedTreatmentAdenocarcinoma of the Lung / Large Cell Lung Cancer / Non-Small Cell Lung Cancer Recurrent / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentChronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2TerminatedTreatmentLung Cancers / Pleural Effusions1
2TerminatedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentStage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2Unknown StatusDiagnosticNeoplasms, Brain1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Unknown StatusTreatmentNemaline Myopathy1
2WithdrawnTreatmentGastrinoma / Glucagonoma / Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma1
2, 3RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Minimal Residual Disease / Philadelphia Chromosome Positive Acute Lymphocytic Leukemia / Tyrosine Kinase Inhibitor1
2, 3RecruitingTreatmentHepatocellular,Carcinoma1
2, 3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentCritical Illness1
3CompletedTreatmentHypersensitivity, Immediate1
3CompletedTreatmentInfant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Sepsis1
3CompletedTreatmentParents2
3Not Yet RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer1
3RecruitingTreatmentALK Gene Rearrangement / ALK Gene Translocation / ALK positive / Stage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage II Non-Small Cell Lung Cancer AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / Ganglioneuroblastoma / INRG Stage L2 / INRG Stage M / INRG Stage MS / Neuroblastomas / NMYC Gene Amplification / Recurrent Neuroblastoma1
3RecruitingTreatmentGeneral Surgery / Parenteral Feeding1
3RecruitingTreatmentGeneral Surgery / Parenteral Nutrition1
3TerminatedTreatmentMalignant Neoplasm of Pancreas1
4Active Not RecruitingTreatmentCritical Illness / Starvation1
4Not Yet RecruitingSupportive CareCritical Illness1
4TerminatedSupportive CareCancer-related Malnutrition1
4TerminatedSupportive CareParenteral Nutrition (No Primary Condition Studied)1
4WithdrawnSupportive CareMalnutrition1
Not AvailableActive Not RecruitingOtherDependence, Cocaine1
Not AvailableCompletedNot AvailableChildhood Acute Myeloid Leukemia/Other Myeloid Malignancies1
Not AvailableCompletedNot AvailableMalignancies1
Not AvailableCompletedBasic ScienceCognitive Flexibility1
Not AvailableCompletedDiagnosticLow Grade Glioma (LGG)1
Not AvailableNot Yet RecruitingNot AvailableCancer, Therapy-Related / Gene fusion / Genetic Alteration / Malignancies / Malignancies Multiple / Malignant Solid Tumours / Molecular Sequence Variation / Receptor Tyrosine Kinase Gene Mutation / RTK Family Gene Mutation1
Not AvailableNot Yet RecruitingNot AvailableNon-squamous, Non-Small Cell Lung Cancer1
Not AvailableRecruitingNot AvailableGastro Intestinal Stromal Tumor1
Not AvailableRecruitingNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableRecruitingNot AvailableMetastatic Non-Small Cell Lung Cancer1
Not AvailableRecruitingOtherAdenocarcinoma of the Lung / Adenosquamous Lung Carcinoma / Large Cell Lung Carcinoma / Lung Large Cell Carcinoma / Resectable Lung Non-Small Cell Carcinoma / Stage IB Lung Non-Small Cell Carcinoma AJCC v7 / Stage IB Lung Squamous Cell Carcinoma AJCC v7 / Stage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IB Squamous Cell Lung Carcinoma / Stage IB Squamous Cell Lung Carcinoma AJCC v7 / Stage II Lung Non-Small Cell Cancer AJCC v7 / Stage II Lung Squamous Cell Carcinoma AJCC v7 / Stage II Non-Small Cell Lung Cancer / Stage II Non-Small Cell Lung Cancer AJCC v7 / Stage II Squamous Cell Lung Carcinoma / Stage II Squamous Cell Lung Carcinoma AJCC v7 / Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 / Stage IIA Lung Squamous Cell Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Squamous Cell Lung Carcinoma / Stage IIA Squamous Cell Lung Carcinoma AJCC v7 / Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 / Stage IIB Lung Squamous Cell Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Squamous Cell Lung Carcinoma / Stage IIB Squamous Cell Lung Carcinoma AJCC v7 / Stage IIIA Lung Non-Small Cell Cancer AJCC v7 / Stage IIIA Lung Squamous Cell Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Squamous Cell Lung Carcinoma / Stage IIIA Squamous Cell Lung Carcinoma AJCC v71
Not AvailableTerminatedBasic ScienceHealthy Volunteers1
Not AvailableTerminatedTreatmentFibromyalgia1
Not AvailableTerminatedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableWithdrawnTreatmentStage II Renal Cell Cancer / Stage III Renal Cell Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Baxter International Inc.
  • Medisca Inc.
  • Spectrum Pharmaceuticals
Dosage forms
FormRouteStrength
LiquidIntravenous
Injection, solutionIntravenous
KitOral
Injection, emulsionIntravenous
Injection, solution, concentrateIntravenous
LiquidHemodialysis
EmulsionIntravenous
SolutionIntravenous
InjectionIntravenous
Prices
Unit descriptionCostUnit
Tyrosine powder1.16USD g
L-tyrosine powder0.94USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)343 dec °CPhysProp
water solubility479 mg/L (at 25 °C)SEIDELL,A (1941)
logP-2.26HANSCH,C ET AL. (1995)
logS-2.57ADME Research, USCD
pKa2.2 (at 25 °C)LEHNINGER,A (1975)
Predicted Properties
PropertyValueSource
Water Solubility7.67 mg/mLALOGPS
logP-2.4ALOGPS
logP-1.5ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)2ChemAxon
pKa (Strongest Basic)9.19ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity47.1 m3·mol-1ChemAxon
Polarizability18.01 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Download (7.36 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-014i-0690000000-cbbf40bb26fc84f2aead
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-014i-0890000000-ca45f993f95c8b0cee44
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-014i-0890000000-5749069211ba15d713ef
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-00xr-9240000000-2c87373c0d964e0edef5
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-014i-0890000000-848b2a4f247a0b3f14e8
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-00xr-9450000000-6d4550940f4dde6f18ff
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-004i-1910000000-5cc19cad5dc24b3b9b11
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-014i-1790000000-de22041357aadf60a06b
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-0690000000-cbbf40bb26fc84f2aead
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-0890000000-ca45f993f95c8b0cee44
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-0890000000-5749069211ba15d713ef
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00xr-9240000000-2c87373c0d964e0edef5
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-014i-0890000000-848b2a4f247a0b3f14e8
GC-MS Spectrum - GC-EI-QQGC-MSsplash10-0udi-3319000000-1d3d28a67f82366fff22
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00xr-9450000000-6d4550940f4dde6f18ff
GC-MS Spectrum - GC-MSGC-MSsplash10-004i-1910000000-5cc19cad5dc24b3b9b11
GC-MS Spectrum - GC-MSGC-MSsplash10-014i-1790000000-de22041357aadf60a06b
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-01p9-0900000000-580de2c16cd24559cd5c
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-0006-9400000000-f233fbc6c58236ee4aeb
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-002f-9100000000-8b5e12eba034bcfdf8a1
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-001i-0920000000-b43356ad3da227b488cb
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-0900000000-c04f0be6515621dda5ac
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-3ed8b68bfade9194763b
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0udi-0900000000-fe6a1ce69851a8c5db00
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-001i-0900000000-aafdcea07be221817fd4
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0002-0900000000-66a5b9a0a48bdc0a2b47
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-0900000000-13eb4252ca23455a58da
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-014i-0900000000-fb85798746829bac3f3d
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-03e9-0839226000-5504e667281c746669ec
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-03di-0900000000-f65cb3ad2fa730c922f7
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-001i-0900000000-a9276fe43ef61b4693e6
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0a59-0039210000-21b4bd9870bf4965a6d1
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-001i-0848491200-aae99eb0b66dd1c7036d
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-03di-0900000000-4104a2ca5d5ef5f22f6d
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-001i-0900000000-f309996d57a95c719deb
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-03di-0013090000-112cd9c2eea42dbc079b
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-001i-0900000000-c7f95918d936586f633d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-03yi-1900000000-d1682546c1e0893c71e4
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-014i-2900000000-a0cc78ed35e56dd812a5
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-00kf-9500000000-d3f399f5dd10e338e25a
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-0006-9200000000-8acd8d370f194bfe28ed
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-001i-0900000000-6b26ce2f5b326ace12a4
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-00ri-0900000000-6f6f9222a3132279b0b3
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-00r6-5900000000-5038b0b81cef20042492
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-0006-9200000000-39be21ca2f5d4dc1d587
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-0006-9000000000-7de0309922df1d7c61b5
MS/MS Spectrum - CE-ESI-TOF (CE-system connected to 6210 Time-of-Flight MS, Agilent) , PositiveLC-MS/MSsplash10-001i-0900000000-a13dba0f14c43b2439d5
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , PositiveLC-MS/MSsplash10-001i-0900000000-e7947aa74e53285a8038
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, PositiveLC-MS/MSsplash10-001i-0900000000-6f37258e3b8ec12255a9
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-001i-1900000000-571c365754ff408549e4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-0900000000-c7f95918d936586f633d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03yi-1900000000-644614c00b6e9f6aef94
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-2900000000-a0cc78ed35e56dd812a5
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00kf-9500000000-d3f399f5dd10e338e25a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9200000000-8acd8d370f194bfe28ed
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-f65cb3ad2fa730c922f7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-a9276fe43ef61b4693e6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a59-0039210000-21b4bd9870bf4965a6d1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0900000000-972f236da42e07f9af17
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-f309996d57a95c719deb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0013090000-112cd9c2eea42dbc079b
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-1900000000-571c365754ff408549e4
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-dae93349deb73168ad0f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00ri-0900000000-b536ea8de6f7d020ec0e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00r6-5900000000-5038b0b81cef20042492
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9200000000-39be21ca2f5d4dc1d587
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-9000000000-7de0309922df1d7c61b5
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-014i-0900000000-e698098d8d8b04bbcc40
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-c04f0be6515621dda5ac
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-3ed8b68bfade9194763b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-fe6a1ce69851a8c5db00
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-66a5b9a0a48bdc0a2b47
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-13eb4252ca23455a58da
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-fb85798746829bac3f3d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-e7947aa74e53285a8038
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001r-0900000000-78c6ce0af62aa6010bcf
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Tyrosine and derivatives
Alternative Parents
Phenylalanine and derivatives / Phenylpropanoic acids / L-alpha-amino acids / Amphetamines and derivatives / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds
show 4 more
Substituents
Tyrosine or derivatives / Phenylalanine or derivatives / 3-phenylpropanoic-acid / Alpha-amino acid / Amphetamine or derivatives / L-alpha-amino acid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / Monocyclic benzene moiety
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
proteinogenic amino acid, L-alpha-amino acid, tyrosine, erythrose 4-phosphate/phosphoenolpyruvate family amino acid (CHEBI:17895) / Common amino acids (C00082)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Tyrosine 3-monooxygenase activity
Specific Function
Plays an important role in the physiology of adrenergic neurons.
Gene Name
TH
Uniprot ID
P07101
Uniprot Name
Tyrosine 3-monooxygenase
Molecular Weight
58599.545 Da
References
  1. Olsovska J, Novotna J, Flieger M, Spizek J: Assay of tyrosine hydroxylase based on high-performance liquid chromatography separation and quantification of L-dopa and L-tyrosine. Biomed Chromatogr. 2007 Dec;21(12):1252-8. [PubMed:17604359]
  2. Bodnar I, Hechtl D, Szekacs D, Olah M, Nagy GM: Effect of local (intracerebral and intracerebroventricular) administration of tyrosine hydroxylase inhibitor on the neuroendocrine dopaminergic neurons and prolactin release. Ideggyogy Sz. 2007 Mar 30;60(3-4):177-81. [PubMed:17451064]
  3. Rostrup M, Fossbakk A, Hauge A, Kleppe R, Gnaiger E, Haavik J: Oxygen dependence of tyrosine hydroxylase. Amino Acids. 2008 Apr;34(3):455-64. Epub 2007 May 23. [PubMed:17520326]
  4. Richards AB, Scheel TA, Wang K, Henkemeyer M, Kromer LF: EphB1 null mice exhibit neuronal loss in substantia nigra pars reticulata and spontaneous locomotor hyperactivity. Eur J Neurosci. 2007 May;25(9):2619-28. [PubMed:17561836]
  5. Ugriumov MV: [Brain neurons partly expressing monoaminergic phenotype: distribution, development, and functional significance]. Usp Fiziol Nauk. 2007 Apr-Jun;38(2):3-25. [PubMed:17578016]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tyrosine-trna ligase activity
Specific Function
Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
Gene Name
YARS2
Uniprot ID
Q9Y2Z4
Uniprot Name
Tyrosine--tRNA ligase, mitochondrial
Molecular Weight
53198.56 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Zhang Y, Wang L, Schultz PG, Wilson IA: Crystal structures of apo wild-type M. jannaschii tyrosyl-tRNA synthetase (TyrRS) and an engineered TyrRS specific for O-methyl-L-tyrosine. Protein Sci. 2005 May;14(5):1340-9. [PubMed:15840835]
  4. Kiga D, Sakamoto K, Kodama K, Kigawa T, Matsuda T, Yabuki T, Shirouzu M, Harada Y, Nakayama H, Takio K, Hasegawa Y, Endo Y, Hirao I, Yokoyama S: An engineered Escherichia coli tyrosyl-tRNA synthetase for site-specific incorporation of an unnatural amino acid into proteins in eukaryotic translation and its application in a wheat germ cell-free system. Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9715-20. Epub 2002 Jul 3. [PubMed:12097643]
  5. Kobayashi T, Nureki O, Ishitani R, Yaremchuk A, Tukalo M, Cusack S, Sakamoto K, Yokoyama S: Structural basis for orthogonal tRNA specificities of tyrosyl-tRNA synthetases for genetic code expansion. Nat Struct Biol. 2003 Jun;10(6):425-32. [PubMed:12754495]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tyrosine-trna ligase activity
Specific Function
Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).
Gene Name
YARS
Uniprot ID
P54577
Uniprot Name
Tyrosine--tRNA ligase, cytoplasmic
Molecular Weight
59143.025 Da
References
  1. Bonnefond L, Frugier M, Touze E, Lorber B, Florentz C, Giege R, Rudinger-Thirion J, Sauter C: Tyrosyl-tRNA synthetase: the first crystallization of a human mitochondrial aminoacyl-tRNA synthetase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Apr 1;63(Pt 4):338-41. Epub 2007 Mar 30. [PubMed:17401211]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Pyridoxal phosphate binding
Specific Function
Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate. Can catalyze the reverse reaction, using glutamic acid, with 2-oxoglutarate as cosubstrate (in vitro). Has...
Gene Name
TAT
Uniprot ID
P17735
Uniprot Name
Tyrosine aminotransferase
Molecular Weight
50398.895 Da
References
  1. Dong S, Kang S, Gu TL, Kardar S, Fu H, Lonial S, Khoury HJ, Khuri F, Chen J: 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood. 2007 Jul 1;110(1):360-9. Epub 2007 Mar 27. [PubMed:17389761]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Very active and specific thyroid hormone transporter. Stimulates cellular uptake of thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and diidothyronine. Does not transport Leu,...
Gene Name
SLC16A2
Uniprot ID
P36021
Uniprot Name
Monocarboxylate transporter 8
Molecular Weight
59510.86 Da
References
  1. Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ: Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem. 2003 Oct 10;278(41):40128-35. Epub 2003 Jul 18. [PubMed:12871948]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
Gene Name
SLC16A10
Uniprot ID
Q8TF71
Uniprot Name
Monocarboxylate transporter 10
Molecular Weight
55492.07 Da
References
  1. Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y, Enomoto A, Cha SH, Goya T, Endou H: The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics. 2002 Jan;79(1):95-103. [PubMed:11827462]
  2. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. [PubMed:11278508]

Drug created on June 13, 2005 07:24 / Updated on December 02, 2019 05:16